BioSapien Inc.

BioSapien has developed a 3D printed biodegradable product that delivers FDA-approved chemotherapy drugs locally to cancerous cells. This novel drug delivery platform technology is called MediChip™.

BioSapien’s lead product is a 3D printed biodegradable drug delivery platform that delivers FDA-approved chemotherapy drugs directly to cancerous cells. This novel technology is called MediChip™. This extended release dosage form provides a localized and sustained release of active pharmaceutical ingredients, The initial therapeutic agent is FDA approved 5-FU for locally advanced GI cancers. Future assets and further MediChip™ programs are focused on immuno-oncology agents and cell therapies. We have had great interest from centers of excellence in the oncology space across the US.

Systemic (IV) chemotherapy has been a major part of cancer care since the 1960s. Even for localized solid tumors, we poison the entire body to destroy this local tissue. We think it is time to change this model.

BioSapien has developed a localized drug delivery platform that is designed to carry one or more active therapeutic agents. The intention is to reduce serious systemic side effects and to increase local penetration of the selected active agents. With a goal to improve patient outcomes and access to care, while reducing hospital and insurance burden.

Our focus is on the high unmet medical need applications in the lower GI oncology to start. Other potential indications include gastric, pancreatic, lung, esophageal, pyloric cancers. The MediChip™ is a drug delivery platform and not restricted to the oncology space. However we believe it could have the greatest impact and the shortest course to market through this avenue.

ELab NYC
SOSV IndieBio